EUVIMEDEUVIMED entdecken
Validierungsstudie

Development and Validation of a HER2-Low Focused Immunohistochemical Scoring System With High-Interobserver Concordance: The Australian HER2-Low Breast Cancer Concordance Study

Gelareh Farshid, Jane Armes, Benjamin Dessauvagie, Amardeep Gilhotra, Beena Kumar, Hema Mahajan, Ewan Millar, Nirmala Pathmanathan, Cameron Snell

Modern Pathology · 2024

DOI: 10.1016/j.modpat.2024.100535 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift Modern Pathology, 2024. Verfasst von Gelareh Farshid und 8 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Medicine, Adelaide University, Adelaide, South Australia, Australia; Discipline of Anatomical Pathology, SA Pathology, Royal Adelaide H…. Hauptthemen laut MEDLINE: Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Immunohistochemistry, Observer Variation. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: AstraZeneca Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The DESTINY Breast-04 trial revealed survival advantages of trastuzumab deruxtecan for women with metastatic HER2-low breast cancer (1+ or 2+ immunohistochemistry [IHC], without amplification). Although this trial applied the 2018 Americal Society of Clinial Oncology (ASCO)/College of American Pathologists (CAP) HER2 IHC scoring criteria, the subjectivity and imprecision in IHC scoring have raised concerns that patients' treatment may be misaligned. Our group of 9 experienced breast pathologists collated a deidentified set of 60 breast cancer core biopsies from 3 laboratories, evaluated with the Ventana 4B5 HER2 assay and mostly scored locally as HER2 0 or 1+. Based on ASCO/CAP 2018 criteria and our extensive experience of reporting HER2 IHC, we specified scoring conventions for cancers with low levels of HER2 protein expression, articulating specific scoring pitfalls. Each pathologist then reviewed digitized whole slide images of the IHC slides and scored the HER2 expression for each case. At a subsequent consensus workshop, we reviewed the cases jointly to establish consensus scores for each case and determine the percentage of HER2 expressing tumor cells. Consensus was reached on all cases, with 40 classified as 1+ and 3 as 2+ (not amplified), totaling 43 (71.7%) HER2-low cancers. The remaining cases were HER2 0. In 93.3% of cases (56/60), the consensus score matched with the majority opinion of pathologists' independent scores. Seven (41.2%) of the 17 cases reported locally as HER2 0 were classified as HER2 low. Conversely, among 32 cases with local scores of 1+, 7 (21.8%) were reclassified as ultralow or null. Individual pathologists' accuracy in matching the consensus scores ranged from 73.3% to 91.67% (mean, 80.74%). Among HER2-low cancers those in which

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesImmunohistochemistryObserver VariationBiomarkers, TumorHumansFemaleAustraliaReproducibility of Results

Stichwörter der Autor:innen

HER2breast cancerimmunohistochemistry

Substanzen

Erb-b2 Receptor Tyrosine KinasesBiomarkers, TumorERBB2 protein, human

Autor:innen und Institutionen

  • Discipline of Medicine, Adelaide University, Adelaide, South Australia, Australia; Discipline of Anatomical Pathology, SA Pathology, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia. Electron…
  • Sullivan Nicolaides Pathology, Birtinya, Queensland, Australia.
  • Clinipath Pathology, Sonic Healthcare Australia Pathology, Osborne Park, Western Australia, Australia; Pathology and Laboratory Medicine, Medical School, The University of Western Australia, Perth, Western Australia, Au…
  • Discipline of Anatomical Pathology, SA Pathology, Royal Adelaide Hospital, North Terrace, Adelaide, South Australia, Australia.
  • Anatomical Pathology and Diagnostic Genomics, Monash Health Pathology, Monash Health, Clayton, Victoria, Australia.
  • NSW Health Pathology, Department of Anatomical Pathology, Westmead Hospital, Sydney, New South Wales, Australia; School of Medicine, The University of Sydney, Camperdown, New South Wales, Australia; School of Medicine,…

Förderung

  • AstraZeneca Australia

Zitieren

APA

Farshid, G., Armes, J., Dessauvagie, B., Gilhotra, A., Kumar, B., Mahajan, H., Millar, E., Pathmanathan, N., & Snell, C. (2024). Development and Validation of a HER2-Low Focused Immunohistochemical Scoring System With High-Interobserver Concordance: The Australian HER2-Low Breast Cancer Concordance Study. Modern Pathology. https://doi.org/10.1016/j.modpat.2024.100535

Vancouver

Farshid G, Armes J, Dessauvagie B, Gilhotra A, Kumar B, Mahajan H, et al. Development and Validation of a HER2-Low Focused Immunohistochemical Scoring System With High-Interobserver Concordance: The Australian HER2-Low Breast Cancer Concordance Study. Modern Pathology. 2024. doi:10.1016/j.modpat.2024.100535

BibTeX
@article{Farshid2024,
  author = {Farshid, Gelareh and Armes, Jane and Dessauvagie, Benjamin and Gilhotra, Amardeep and Kumar, Beena and Mahajan, Hema and Millar, Ewan and Pathmanathan, Nirmala and Snell, Cameron},
  title = {Development and Validation of a HER2-Low Focused Immunohistochemical Scoring System With High-Interobserver Concordance: The Australian HER2-Low Breast Cancer Concordance Study},
  journal = {Modern Pathology},
  year = {2024},
  doi = {10.1016/j.modpat.2024.100535}
}
Kostenlos starten →